A Colton-supported NYU study published in Science Immunology has discovered that the immune checkpoint protein PD-1 functions as a dimer — a finding that could transform drug design for both cancer and autoimmune disease.
Penn Medicine's Colton Center is leading a new wave of precision immunotherapy for autoimmune disease — from CAAR T cell therapy for pemphigus to immune profiling tools that could one day cure these conditions.
NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.
Tel Aviv University's Colton Center for Autoimmunity joins a four-university consortium dedicated to finding cures for over 100 autoimmune diseases through big data analytics, multidisciplinary research, and international collaboration.
Penn Medicine's new Colton Center for Autoimmunity unites the university's immunology research and patient care programs, joining NYU and Yale in a shared effort to advance autoimmune disease diagnosis and treatment.
Yale's Colton Center for Autoimmunity has awarded 2022 grants to six projects spanning lupus, multiple sclerosis, pediatric OCD, and systemic sclerosis — all targeting new diagnostics, therapies, or disease mechanisms.
NYU Langone's Colton-backed Division of Rheumatology is taking a leading role in the NIH's $58 million AMP AIM program, driving research into lupus, psoriatic disease, Sjögren's disease, and the microbiome.
Yale Medicine Magazine profiles Colton-funded researchers using skin as a diagnostic and therapeutic entry point into autoimmune disease — from scleroderma antibody therapy to cancer-triggered bullous pemphigoid.
Colton-supported NYU researchers have found that autoantibodies can physically inactivate a key enzyme in over half of lupus nephritis patients — a non-genetic mechanism that could serve as a future biomarker and therapeutic target.
NYU Langone's Colton Center has funded seven new autoimmune pilot projects for 2019 — targeting myasthenia gravis, rheumatoid arthritis, and lupus — while earlier grants advance toward clinical diagnostics and therapies.
